Related references
Note: Only part of the references are listed.Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
Alessandra Larocca et al.
BLOOD (2021)
MAIA under the microscope - bringing trial design into focus
Prashant Kapoor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Geriatric Assessment in Older Adults with Multiple Myeloma
Tanya M. Wildes et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen et al.
HAEMATOLOGICA (2013)
End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology Position Article
Hans Wildiers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
T Facon et al.
BLOOD (2006)
Share Paper
